CellCyte Shares Ride a Wave of Hype

For years, the founders of CellCyte Genetics relied on infusions from angel investors to keep their tiny startup afloat. But after Kirkland-based CellCyte combined with a moribund public company, its shares caught fire this fall in the loosely regulated over-the-counter (OTC) market and on Germany’s Frankfurt Stock Exchange.
The Seattle Times